Nuvo Subsidiary Obtains Rights to Resultz

Pharmaceutical Investing

Nuvo Pharmaceuticals (TSX:NRI; OTCQX:NRIFF) announced its Ireline subsidiary acquired the U.S. rights of Resultz from Piedmont Pharmaceuticals. As quoted in the press release: The acquisition includes all U.S. product and intellectual property rights and is a complementary follow-on to Nuvo’s acquisition of the global, ex-U.S. Resultz product rights announced on January 2, 2018. Nuvo now owns all Resultz product …

Nuvo Pharmaceuticals (TSX:NRI; OTCQX:NRIFF) announced its Ireline subsidiary acquired the U.S. rights of Resultz from Piedmont Pharmaceuticals.
As quoted in the press release:

The acquisition includes all U.S. product and intellectual property rights and is a complementary follow-on to Nuvo’s acquisition of the global, ex-U.S. Resultz product rights announced on January 2, 2018. Nuvo now owns all Resultz product and intellectual property rights throughout the world.
“We are thrilled to complete full ownership of the global Resultz business through the acquisition of the U.S. rights for Resultz,” said Jesse Ledger, Nuvo’s President & CEO. “We believe the product attributes that have made Resultz a market leader in Canada and Europe, where market capture rates have reached as high as 35%, namely the class-leading 5-minute application time, up to 100% efficacy and exceptional safety profile as a non-pesticide treatment, will make it a success in the United States as well.”

Click here to read the full press release.

Source: www.newswire.ca

acquisition application canada europe jesse ledger nuvo pharmaceuticals united states Pharmaceutical Investing